

APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



10th August 2018

The Secretary,
Bombay Stock Exchange Ltd (BSE)
Phiroze Jheejheebhoy Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code - 508869
ISIN INE437A01024

The Secretary,
National Stock Exchange,
Exchange Plaza, 5th Floor
Plot No.C/1, 'G' Block
Bandra - Kurla Complex
Bandra (E)
Mumbai - 400 051.
Scrip Code-
APOLLOHOSP
ISIN INE437A01024

The Manager
The National Stock
Exchange,
Wholesale Debt Market
Exchange Plaza, 5th Floor
Plot No.C/1, 'G' Block
Bandra - Kurla Complex
Bandra (E)
Mumbai - 400 051.
ISIN INE437A07062,
INE437A07070,
INE437A07088 &
INE437A07093

Dear Sir,

Sub: Unaudited Financial Results for the quarter ended 30th June 2018

Further to our letters dated 12th July 2018, the Board of Directors at its meeting held on 10th August 2018 have approved the unaudited financial results of the Company for the quarter ended 30th June 2018.

As required by the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, (LODR) we enclose/furnish the following particulars.

Financial Results

1. Unaudited Standalone financial results of the Company for the quarter ended 30th June 2018, which have been subjected to Limited Review by the Statutory Auditors of the Company.
2. Copy of the Limited Review Report of the Statutory Auditors for the corresponding period.
3. The financial results will also be published in the newspapers, in the format prescribed under Regulation 47 of the Listing Regulations read with SEBI circular dated 10th August 2016.
4. The said documents are being posted on the website of the Company i.e., www.apollohospitals.com.

IS/ISO 9001:2000

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers", III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : apolloshares@vsnl.net
Website: www.apollohospitals.com

APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



Schedule of Conference Call

Pursuant to Regulation 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a conference call for the analysts/investors is scheduled to be held on Saturday, 11th August 2018 at 12.30 p.m.. to discuss the financial results for the quarter ended 30th June 2018.

The meeting of the Board of Directors commenced at 11.00 a.m. and concluded at 1:30 p.m.

You are requested to kindly take note of the same in your records.

Thanking You

Yours faithfully
For APOLLO HOSPITALS ENTERPRISE LIMITED

S.M. KRISHNAN
VICE PRESIDENT - FINANCE
AND COMPANY SECRETARY

CC : The Secretary,
Luxembourg Stock Exchange,
B.P. 165,
L-2011 Luxembourg.

Securities and Exchange Commission
Division of Corporation Finance
Office of International Corporate Finance
450 Fifth Street, N.W.
Washington, D.C
20549-0302
File No. 82-34893

Ref : ISIN US0376081065 - Rule 144a GDR
ISIN US0376082055 - Reg. S GDR

IS/ISO 9001:2000

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers", III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : apolloshares@vsnl.net
Website: www.apollohospitals.com

1. Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2018

Particulars	(Rs. In lakhs)			
	Three months ended 30/06/2018	Preceding Three months ended 31/03/2018	Corresponding Three months ended 30/06/2017	Previous year ended 31/03/2018
	Unaudited	Unaudited (Refer Note 2)	Unaudited (Refer Note 2)	Audited
1 Income				
(a) Revenue from Operations	191,039	186,292	165,036	718,301
(b) Other Income	205	584	(354)	1,259
Total Income	191,244	186,876	164,682	719,560
2 Expenses				
(a) Cost of Materials Consumed	32,422	32,037	30,774	126,800
(b) Purchase of Stock-in-Trade	74,731	67,834	63,546	261,422
(c) Changes in inventories of stock-in-trade	(6,233)	(1,896)	(5,822)	(8,092)
(d) Employee Benefits Expense	29,586	29,086	26,122	111,881
(e) Finance Costs	6,207	6,242	5,546	24,017
(f) Depreciation and amortisation expense	7,240	7,314	6,464	27,200
(g) Other Expenses	37,868	37,873	33,074	143,319
Total Expenses	181,821	178,490	159,704	686,547
3 Profit before exceptional item and tax (1) - (2)	9,423	8,386	4,978	33,013
4 Exceptional Items	-	-	-	-
5 Profit before tax (3) - (4)	9,423	8,386	4,978	33,013
6 Tax Expenses				
Current Tax (Refer Note 5)	2,406	2,251	1,074	7,435
Deferred Tax	1,001	171	383	2,258
7 Profit for the period / year (5) - (6)	6,016	5,964	3,521	23,320
8 Other Comprehensive Income				
Items that will not be reclassified to Profit and Loss				
-Remeasurement gains/(losses) on defined benefit plan	(1,533)	102	(974)	(2,790)
-Tax on above	536	(35)	337	966
Other Comprehensive Income / (Loss)	(997)	67	(637)	(1,824)
9 Total Comprehensive Income for the period / year (after tax) (7) + (8)	5,019	6,031	2,884	21,496
10 Paid-up equity share capital (Face value Rs.5/- per share)				6,956
Reserves (excluding Revaluation Reserves)				362,392
11 Earnings per equity share of Rs.5/- each				
Basic and Diluted EPS before extraordinary items for the period (Rs.)	*4.32	*4.29	*2.53	16.76
Basic and Diluted EPS after extraordinary items for the period (Rs.)	*4.32	*4.29	*2.53	16.76
Additional Information :-				
Earnings before finance costs, tax, depreciation and amortization, exceptional items (EBITDA)	22,665	21,358	17,342	82,971

*Not annualised

Notes:

- The unaudited standalone financial results for the quarter ended June 30, 2018 have been reviewed by the Audit Committee and approved by the Board of Directors in their meetings held on 9th and 10th August 2018 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have issued an unqualified review conclusion.
- The standalone financial results for the three months ended March 31, 2018 is the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to December 31, 2017. Amounts for the three months ended June 30, 2017 were reviewed by the previous auditors.
- In June 2018, the Company acquired 50% equity stake in Medics International Lifesciences Limited for a consideration of Rs. 9,102.50 lakhs.
- Effective April 1, 2018, the Company adopted Ind AS 115 - Revenue from contracts with customers, using the cumulative catch-up transition method which is applied to contracts that were not completed as of April 1, 2018. Accordingly, the comparatives have not been retrospectively adjusted. The effect of adoption of Ind AS 115 is insignificant.
- Current tax includes an amount of Rs. 414 lakhs provided during the quarter ended June 30, 2018 relating to earlier assessment years, consequent to the completion of the income tax proceedings by the relevant authority during the quarter.
- The secured listed non-convertible debentures of the Company aggregating to Rs. 7,000 lakhs as on June 30, 2018 are secured by way of first mortgage/charge on the Company's properties. The asset cover on the secured listed non-convertible debentures of the Company exceeds hundred percent of the principal amount of the said debentures.
- Figures for the previous periods / year are reclassified / regrouped wherever necessary.

Place : Chennai
Date : August 10, 2018



for APOLLO HOSPITALS ENTERPRISE LIMITED
For APOLLO HOSPITALS ENTERPRISE LTD.
 DR. PRATHAP C REDDY
 Executive Chairman

Suneeta Reddy
 Managing Director

Apollo Hospitals Enterprise Limited
 Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai-28, Tamil Nadu

2. Segment wise Revenue, Results, Segment Assets and Segment Liabilities

(Rs. In lakhs)

Particulars	Three months ended 30/06/2018	Preceding Three months ended 31/03/2018	Corresponding Three months ended 30/06/2017	Previous year ended 31/03/2018
	Unaudited	Unaudited (Refer Note 2)	Unaudited (Refer Note 2)	Audited
1. Segment Revenue				
a) Healthcare Services	101,899	100,002	90,761	391,478
b) Pharmacy	89,207	86,308	74,289	326,888
c) Others	205	584	(354)	1,259
SUB - TOTAL	191,311	186,894	164,696	719,625
Less : Intersegmental Revenue	67	17	14	65
Income from Operations	191,244	186,877	164,682	719,560
2. Segment Results				
a) Healthcare Services	12,097	10,851	8,410	44,033
b) Pharmacy	3,328	3,193	2,468	11,738
c) Others	205	584	(354)	1,259
SUB - TOTAL	15,630	14,628	10,524	57,030
Less : (i) Finance Cost	6,207	6,242	5,546	24,017
(ii) Other un-allocable expenditure	-	-	-	-
Profit Before Tax	9,423	8,386	4,978	33,013
3. Segments Assets				
a) Healthcare Services *	580,202	584,114	547,709	584,114
b) Pharmacy	103,774	93,724	84,359	93,724
c) Others	110,089	92,070	98,181	92,070
d) Unallocable Assets	11,905	11,297	14,088	11,297
Total	805,970	781,205	744,337	781,205
4. Segments Liabilities				
a) Healthcare Services	75,737	72,674	70,217	72,674
b) Pharmacy	17,451	15,389	17,513	15,389
c) Others	-	-	-	-
d) Unallocable Liabilities	338,413	323,794	295,866	323,794
Total	431,601	411,857	383,596	411,857
* Includes segment assets in various hospital projects under construction	70,212	69,830	35,284	69,830

Place : Chennai
 Date : August 10, 2018

for APOLLO HOSPITALS ENTERPRISE LIMITED

DR. PRATHAP C REDDY
 Executive Chairman



For APOLLO HOSPITALS ENTERPRISE LTD.

Suneeta Reddy
 Suneeta Reddy
 Managing Director

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu

Tel. +91-44-28290956, Fax.+91-44-28290956, Email: investor.relations@apollohospitals.com,

Website : www.apollohospitals.com

**Extract of Statement of Standalone Unaudited Financial Results
for the Quarter Ended 30th June 2018**

(Rs. in Lakhs, except per share data)

Particulars	Three months ended 30/06/2018	Preceding Three months ended 31/03/2018	Corresponding Three months ended 30/06/2017	Previous year ended 31/03/2018
	Unaudited	Unaudited Refer Note No. 3	Unaudited Refer Note No. 3	Audited
Total Income from Operations (net)	1,91,244	1,86,876	1,64,682	7,19,560
Net Profit /(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	9,423	8,386	4,978	33,013
Net Profit /(Loss) for the period (before Tax, after Exceptional and/or Extraordinary Items)	9,423	8,386	4,978	33,013
Net profit /(Loss) for the period after tax (after Exceptional and Extraordinary items)	6,016	5,964	3,521	23,320
Total Comprehensive Income for the period [comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	5,019	6,031	2,884	21,496
Paid up Equity Share Capital (Face value of Rs.5/- each)	6,956	6,956	6,956	6,956
Other Equity				3,62,392
Earnings Per Share of Rs. 5/- each				
Basic	*4.32	*4.29	*2.53	16.76
Diluted	*4.32	*4.29	*2.53	16.76

* Not Annualised

Notes

1 The above is an extract of the detailed format of standalone quarterly financial results filed with stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financials for the quarter s ended 30th June 2018 are available on the stock exchange websites www. nseindia.com and www.bseindia.com and also the company's website www.apollohospitals.com

2 The unaudited standalone financial results for the quarter ended June 30, 2018 have been reviewed by the Audit Committee and approved by the Board of Directors in their meetings held on 9th and 10th August 2018 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have issued an unqualified review conclusion.

3 The standalone financial results for the three months ended March 31, 2018 is the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to December 31, 2017. Amounts for the three months ended June 30, 2017 were reviewed by the previous auditors.

4 In June 2018, the Company acquired 50% equity stake in Medics International Lifesciences Limited, Lucknow for a consideration of Rs. 9,102.50 lakhs.

5 Effective April 1, 2018, the Company adopted Ind AS 115 - Revenue from contracts with customers, using the cumulative catch-up transition method which is applied to contracts that were not completed as of April 1, 2018. Accordingly, the comparatives have not been retrospectively adjusted. The effect of adoption of Ind AS 115 is insignificant.

6 Current tax includes an amount of Rs. 414 lakhs provided during the quarter ended June 30, 2018 relating to earlier assessment years, consequent to the completion of the income tax proceedings by the relevant authority during the quarter.

7 The secured listed non-convertible debentures of the Company aggregating to Rs. 7,000 lakhs as on June 30, 2018 are secured by way of of first mortgage/charge on the Company's properties. The asset cover on the secured listed non-convertible debentures of the Company exceeds hundred percent of the principal amount of the said debentures

8 Figures for the previous periods / year are reclassified / regrouped wherever necessary.

for APOLLO HOSPITALS ENTERPRISE LIMITED

For APOLLO HOSPITALS ENTERPRISE LTD.

Place : Chennai
Date : August 10, 2018


Suneeta Reddy
Managing Director

DR. PRATHAP C REDDY
Executive Chairman
(DIN : 00003654)

**INDEPENDENT AUDITOR'S REVIEW REPORT
ON REVIEW OF INTERIM FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
APOLLO HOSPITALS ENTERPRISE LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **APOLLO HOSPITALS ENTERPRISE LIMITED** ("the Company"), for the quarter ended June 30, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Vikas Bagaria
Partner

(Membership No. 060408)

BENGALURU, August 10, 2018